Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

The following table summarizes the segment information (in thousands):


	Three Months Ended March 31,
	2022		2021
Net revenues:
Clinical Services	$	98,791	$	96,487
Pharma Services	18,378		19,046
Total revenue	117,169		115,533

Cost of revenue:
Clinical Services(1)	65,267		61,565
Pharma Services(2)	13,670		12,394
Total cost of revenue	78,937		73,959

Gross Profit:
Clinical Services	33,524		34,922
Pharma Services	4,708		6,652
Total gross profit	38,232		41,574

Operating expenses:
General and administrative	66,248		40,476
Research and development	7,713		2,456
Sales and marketing	16,299		13,749
Total operating expenses	90,260		56,681
Loss from operations	(52,028)		(15,107)
Interest (income) expense, net	1,301		1,177
Other (income) expenses, net	(168)		4,854



Loss before taxes	(53,161)		(21,138)
Income tax (benefit) expense	(3,753)		976
Net loss	$	(49,408)	$	(22,114)

(1) Clinical Services cost of revenue includes $4.3 million of amortization of acquired Inivata developed technology for the three months ended March 31, 2022. Clinical Services cost of revenue includes write-offs of $5.3 million for COVID-19 PCR testing inventory for the three months ended March 31, 2021.

(2) Pharma Services cost of revenue for the three months ended March 31, 2022 includes $0.6 million of amortization of acquired Inivata developed technology intangible assets. There were no such amounts for the three months ended March 31, 2021.